[go: up one dir, main page]

WO2003104811A3 - DIAGNOSTIC AND THERAPEUTIC USE OF THE ACUTE STEROIDOGEN RESPONSE REGULATORY PROTEIN FOR TREATING NEURODEGENERATIVE DISEASES - Google Patents

DIAGNOSTIC AND THERAPEUTIC USE OF THE ACUTE STEROIDOGEN RESPONSE REGULATORY PROTEIN FOR TREATING NEURODEGENERATIVE DISEASES Download PDF

Info

Publication number
WO2003104811A3
WO2003104811A3 PCT/EP2003/005910 EP0305910W WO03104811A3 WO 2003104811 A3 WO2003104811 A3 WO 2003104811A3 EP 0305910 W EP0305910 W EP 0305910W WO 03104811 A3 WO03104811 A3 WO 03104811A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
acute
regulatory protein
neurodegenerative diseases
steroidogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/005910
Other languages
French (fr)
Other versions
WO2003104811A2 (en
Inventor
Thomas Hesterkamp
Der Kammer Heinz Von
Ralf Krappa
Johannes Pohlner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evotec Neurosciences GmbH
Original Assignee
Evotec Neurosciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Neurosciences GmbH filed Critical Evotec Neurosciences GmbH
Priority to EP03730155A priority Critical patent/EP1512013A2/en
Priority to AU2003240746A priority patent/AU2003240746A1/en
Priority to US10/517,439 priority patent/US20070118913A1/en
Priority to JP2004511831A priority patent/JP2005531305A/en
Publication of WO2003104811A2 publication Critical patent/WO2003104811A2/en
Publication of WO2003104811A3 publication Critical patent/WO2003104811A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne l'expression différente du gène de la protéine régulatrice de réponse stéroïdogène aigüe (StAR) dans des régions spécifiques du cerveau de patients atteints de la maladie d'Alzheimer. Fondée sur cette découverte, l'invention concerne un procédé permettant de diagnostiquer ou de pronostiquer chez un sujet une maladie neurodégénérative, en particulier la maladie d'Alzheimer, ou de déterminer si un sujet présente un risque accru de développer une telle maladie. L'invention concerne de plus des méthodes de traitement et de prévention de la maladie d'Alzheimer et de troubles neurodégénératifs apparentés, au moyen du gène StAR et de produits géniques correspondants. Un procédé de criblage d'agents modulateurs de maladies neurodégénératives est également décrit.The invention relates to the different expression of the gene for the acute steroidogenic response regulatory protein (StAR) in specific regions of the brain of patients suffering from Alzheimer's disease. Based on this discovery, the invention relates to a method for diagnosing or prognosing in a subject a neurodegenerative disease, in particular Alzheimer's disease, or for determining whether a subject is at increased risk of developing such a disease. The invention further relates to methods of treating and preventing Alzheimer's disease and related neurodegenerative disorders using the StAR gene and corresponding gene products. A method of screening for modulating agents of neurodegenerative diseases is also described.

PCT/EP2003/005910 2002-05-17 2003-06-05 Diagnostic and therapeutic use of steroidogenic acute regulatory protein for neurodegenerative diseases Ceased WO2003104811A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP03730155A EP1512013A2 (en) 2002-06-10 2003-06-05 Diagnostic and therapeutic use of steroidogenic acute regulatory protein for neurodegenerative diseases
AU2003240746A AU2003240746A1 (en) 2002-06-10 2003-06-05 Diagnostic and therapeutic use of steroidogenic acute regulatory protein for neurodegenerative diseases
US10/517,439 US20070118913A1 (en) 2002-05-17 2003-06-05 Diagnostic and therapeutic use of steroidogenic acute regulatory protein for neurodegenerative diseases
JP2004511831A JP2005531305A (en) 2002-06-10 2003-06-05 Diagnostic and therapeutic uses of steroidogenic acute regulatory proteins for neurodegenerative diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38672102P 2002-06-10 2002-06-10
US60/386,721 2002-06-10
EP02012815.3 2002-06-10
EP02012815 2002-06-10

Publications (2)

Publication Number Publication Date
WO2003104811A2 WO2003104811A2 (en) 2003-12-18
WO2003104811A3 true WO2003104811A3 (en) 2004-10-14

Family

ID=56290436

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/005910 Ceased WO2003104811A2 (en) 2002-05-17 2003-06-05 Diagnostic and therapeutic use of steroidogenic acute regulatory protein for neurodegenerative diseases

Country Status (4)

Country Link
EP (1) EP1512013A2 (en)
JP (1) JP2005531305A (en)
AU (1) AU2003240746A1 (en)
WO (1) WO2003104811A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021394760A1 (en) * 2020-12-08 2023-07-06 Repair Biotechnologies, Inc. Enhancing mitochondrial-based flow and catabolism of cholesterol
CN119790165A (en) * 2022-07-01 2025-04-08 田边三菱制药株式会社 Compositions and methods for assessing edaravone responsiveness
KR102885777B1 (en) * 2022-09-08 2025-11-13 차의과학대학교 산학협력단 Biomarkers for the diagnosis of infertility in elderly women and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
WO1999052519A2 (en) * 1998-04-14 1999-10-21 The General Hospital Corporation Methods for treating neuropsychiatric disorders
WO2000066728A1 (en) * 1999-05-03 2000-11-09 Compugen Ltd. StAR HOMOLOGUES
WO2001032920A2 (en) * 1999-11-03 2001-05-10 Metris Therapeutics Limited Agents implicated in endometriosis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
WO1999052519A2 (en) * 1998-04-14 1999-10-21 The General Hospital Corporation Methods for treating neuropsychiatric disorders
WO2000066728A1 (en) * 1999-05-03 2000-11-09 Compugen Ltd. StAR HOMOLOGUES
WO2001032920A2 (en) * 1999-11-03 2001-05-10 Metris Therapeutics Limited Agents implicated in endometriosis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CARON KATHLEEN M ET AL: "Targeted disruption of the mouse gene encoding steroidogenic acute regulatory protein provides insights into congenital lipoid adrenal hyperplasia.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 94, no. 21, 1997, 1997, pages 11540 - 11545, XP002241664, ISSN: 0027-8424 *
KALLEN C B ET AL: "UNVEILING THE MECHANISM OF ACTION AND REGULATION OF THE STEROIDOGENIC ACUTE REGULATORY PROTEIN", MOLECULAR AND CELLULAR ENDOCRINOLOGY, AMSTERDAM, NL, vol. 145, no. 1/2, 25 October 1998 (1998-10-25), pages 39 - 45, XP000900751, ISSN: 0303-7207 *
KIMOTO TETSUYA ET AL: "Neurosteroid synthesis by cytochrome P450-containing systems localized in the rat brain hippocampal neurons: N-methyl-D-aspartate and calcium-dependent synthesis.", ENDOCRINOLOGY, vol. 142, no. 8, August 2001 (2001-08-01), pages 3578 - 3589, XP002241665, ISSN: 0013-7227 *
STOCCO DOUGLAS M: "Tracking the role of a StAR in the sky of the new millennium.", MOLECULAR ENDOCRINOLOGY, vol. 15, no. 8, August 2001 (2001-08-01), pages 1245 - 1254, XP002241663, ISSN: 0888-8809 *

Also Published As

Publication number Publication date
WO2003104811A2 (en) 2003-12-18
AU2003240746A1 (en) 2003-12-22
AU2003240746A8 (en) 2003-12-22
JP2005531305A (en) 2005-10-20
EP1512013A2 (en) 2005-03-09

Similar Documents

Publication Publication Date Title
Schimmenti et al. Further delineation of renal-coloboma syndrome in patients with extreme variability of phenotype and identical PAX2 mutations
Chung et al. Early onset severe and late-onset mild Charcot–Marie–Tooth disease with mitofusin 2 (MFN2) mutations
Xie et al. New syndrome with retinitis pigmentosa is caused by nonsense mutations in retinol dehydrogenase RDH11
Tsang et al. A novel mutation and phenotypes in phosphodiesterase 6 deficiency
Gartner et al. Novel variants in SPTAN1 without epilepsy: an expansion of the phenotype
Volk et al. Biallelic mutations in L-dopachrome tautomerase (DCT) cause infantile nystagmus and oculocutaneous albinism
Skorczyk-Werner et al. Novel gene variants in Polish patients with Leber congenital amaurosis (LCA)
Khan et al. PDCD6IP, encoding a regulator of the ESCRT complex, is mutated in microcephaly
Sahly et al. Prominent neuronal-specific tub gene expression in cellular targets of tubby mice mutation
van der Heide et al. Exome-based investigation of the genetic basis of human pigmentary glaucoma
WO2003104811A3 (en) DIAGNOSTIC AND THERAPEUTIC USE OF THE ACUTE STEROIDOGEN RESPONSE REGULATORY PROTEIN FOR TREATING NEURODEGENERATIVE DISEASES
Tippett et al. The complexity of clinical Huntington’s disease: developments in molecular genetics, neuropathology and neuroimaging biomarkers
Zeineddin et al. A novel pathogenic variant in the KCTD7 gene in a patient with neuronal ceroid lipofuscinosis (CLN14): a case report and review of the literature
WO2002016636A3 (en) Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders
Cohen et al. Neuropsychiatric disorders of childhood: Tourette's syndrome as a model
Faqeih et al. Novel STAMBP mutation and additional findings in an Arabic family
WO2004003563A3 (en) Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases
Skorczyk-Werner et al. Molecular background of Leber congenital amaurosis in a Polish cohort of patients—novel variants discovered by NGS
AU2003224120A1 (en) Diagnostic and therapeutic use of ensadin-0477 gene and protein for neurodegenerative diseases
Szaflarska et al. Neurodegenerative changes detected by neuroimaging in a patient with contiguous X-chromosome deletion syndrome encompassing BTK and TIMM8A genes
WO2004001422A3 (en) Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases
Ohira et al. CLCN2-related leukoencephalopathy with novel compound heterozygous variants followed with magnetic resonance imaging over 17 years: a case report
Ray et al. Calpain and calpastatin expression in primary oligodendrocyte culture: preferential localization of membrane calpain in cell processes
WO2004038411A3 (en) Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases
van Renterghem et al. Two siblings with Bosch-Boonstra-Schaaf optic atrophy syndrome due to parental gonadal mosaicism

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003730155

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004511831

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003730155

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007118913

Country of ref document: US

Ref document number: 10517439

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10517439

Country of ref document: US